Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$0.37 USD
-0.02 (-6.12%)
Updated Aug 13, 2024 03:59 PM ET
After-Market: $0.36 -0.01 (-1.88%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RDHL 0.37 -0.02(-6.12%)
Will RDHL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RDHL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RDHL
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
RDHL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for RDHL
RedHill Biopharma Schedules Annual Shareholders Meet
RedHill Biopharma Gears Up for Key Shareholder Meeting
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
RedHill Biopharma's RHB-104 shows positive Phase 3 results in Crohn's Disease